167 related articles for article (PubMed ID: 20808785)
1. Structural basis for certain naturally occurring bioflavonoids to function as reducing co-substrates of cyclooxygenase I and II.
Wang P; Bai HW; Zhu BT
PLoS One; 2010 Aug; 5(8):e12316. PubMed ID: 20808785
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cyclooxygenase by blocking the reducing cosubstrate at the peroxidase site: Discovery of galangin as a novel cyclooxygenase inhibitor.
Bai HW; Yang C; Wang P; Rao S; Zhu BT
Eur J Pharmacol; 2021 May; 899():174036. PubMed ID: 33737009
[TBL] [Abstract][Full Text] [Related]
3. Strong activation of cyclooxygenase I and II catalytic activity by dietary bioflavonoids.
Bai HW; Zhu BT
J Lipid Res; 2008 Dec; 49(12):2557-70. PubMed ID: 18660529
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of molecular modeling in characterizing the ligand-binding sites of proteins: experience with human PDI, PDIp and COX.
Wang P; Zhu BT
Curr Med Chem; 2013; 20(31):3840-54. PubMed ID: 23931275
[TBL] [Abstract][Full Text] [Related]
5. Isoxazole-Based-Scaffold Inhibitors Targeting Cyclooxygenases (COXs).
Perrone MG; Vitale P; Panella A; Ferorelli S; Contino M; Lavecchia A; Scilimati A
ChemMedChem; 2016 Jun; 11(11):1172-87. PubMed ID: 27136372
[TBL] [Abstract][Full Text] [Related]
6. Thiazole derivatives as inhibitors of cyclooxygenases in vitro and in vivo.
El-Achkar GA; Jouni M; Mrad MF; Hirz T; El Hachem N; Khalaf A; Hammoud S; Fayyad-Kazan H; Eid AA; Badran B; Merhi RA; Hachem A; Hamade E; Habib A
Eur J Pharmacol; 2015 Mar; 750():66-73. PubMed ID: 25617797
[TBL] [Abstract][Full Text] [Related]
7. Myricetin and quercetin are naturally occurring co-substrates of cyclooxygenases in vivo.
Bai HW; Zhu BT
Prostaglandins Leukot Essent Fatty Acids; 2010 Jan; 82(1):45-50. PubMed ID: 19897347
[TBL] [Abstract][Full Text] [Related]
8. Computer aided drug design approaches to develop cyclooxygenase based novel anti-inflammatory and anti-cancer drugs.
Reddy RN; Mutyala R; Aparoy P; Reddanna P; Reddy MR
Curr Pharm Des; 2007; 13(34):3505-17. PubMed ID: 18220787
[TBL] [Abstract][Full Text] [Related]
9. Molecular dynamics simulations of arachidonic acid complexes with COX-1 and COX-2: insights into equilibrium behavior.
Furse KE; Pratt DA; Porter NA; Lybrand TP
Biochemistry; 2006 Mar; 45(10):3189-205. PubMed ID: 16519514
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of reactivation of the peroxidase catalytic activity of human cyclooxygenases by reducing cosubstrate quercetin.
Yang C; Li P; Wang P; Zhu BT
J Mol Graph Model; 2021 Sep; 107():107941. PubMed ID: 34091174
[TBL] [Abstract][Full Text] [Related]
11. Indole based cyclooxygenase inhibitors: synthesis, biological evaluation, docking and NMR screening.
Estevão MS; Carvalho LC; Freitas M; Gomes A; Viegas A; Manso J; Erhardt S; Fernandes E; Cabrita EJ; Marques MM
Eur J Med Chem; 2012 Aug; 54():823-33. PubMed ID: 22796043
[TBL] [Abstract][Full Text] [Related]
12. Chemical and structural diversity in cyclooxygenase protein active sites.
Huff RG; Bayram E; Tan H; Knutson ST; Knaggs MH; Richon AB; Santago P; Fetrow JS
Chem Biodivers; 2005 Nov; 2(11):1533-52. PubMed ID: 17191953
[TBL] [Abstract][Full Text] [Related]
13. Docking-based 3D-QSAR (CoMFA, CoMFA-RG, CoMSIA) study on hydroquinoline and thiazinan-4-one derivatives as selective COX-2 inhibitors.
Dowlati Beirami A; Hajimahdi Z; Zarghi A
J Biomol Struct Dyn; 2019 Jul; 37(11):2999-3006. PubMed ID: 30035675
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory mode of 1,5-diarylpyrazole derivatives against cyclooxygenase-2 and cyclooxygenase-1: molecular docking and 3D QSAR analyses.
Liu H; Huang X; Shen J; Luo X; Li M; Xiong B; Chen G; Shen J; Yang Y; Jiang H; Chen K
J Med Chem; 2002 Oct; 45(22):4816-27. PubMed ID: 12383007
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, anti-inflammatory, analgesic, COX-1/2 inhibitory activities and molecular docking studies of substituted 2-mercapto-4(3H)-quinazolinones.
Abdel-Aziz AA; Abou-Zeid LA; ElTahir KEH; Ayyad RR; El-Sayed MA; El-Azab AS
Eur J Med Chem; 2016 Oct; 121():410-421. PubMed ID: 27318118
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, biological evaluation, docking study and ulcerogenicity profiling of some novel quinoline-2-carboxamides as dual COXs/LOX inhibitors endowed with anti-inflammatory activity.
Abdelrahman MH; Youssif BGM; Abdelgawad MA; Abdelazeem AH; Ibrahim HM; Moustafa AEGA; Treamblu L; Bukhari SNA
Eur J Med Chem; 2017 Feb; 127():972-985. PubMed ID: 27837994
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, anti-inflammatory activity and molecular docking studies of 2,5-diarylfuran amino acid derivatives.
Stefani HA; Botteselle GV; Zukerman-Schpector J; Caracelli I; da Silva Corrêa D; Farsky SH; Machado ID; Santin JR; Hebeda CB
Eur J Med Chem; 2012 Jan; 47(1):52-8. PubMed ID: 22071254
[TBL] [Abstract][Full Text] [Related]
18. Stimulation of the Production of Prostaglandin E₂ by Ethyl Gallate, a Natural Phenolic Compound Richly Contained in Longan.
Wang HR; Sui HC; Ding YY; Zhu BT
Biomolecules; 2018 Sep; 8(3):. PubMed ID: 30200641
[TBL] [Abstract][Full Text] [Related]
19. The Molecular Basis for Dual Fatty Acid Amide Hydrolase (FAAH)/Cyclooxygenase (COX) Inhibition.
Palermo G; Favia AD; Convertino M; De Vivo M
ChemMedChem; 2016 Jun; 11(12):1252-8. PubMed ID: 26593700
[TBL] [Abstract][Full Text] [Related]
20. Deciphering the mechanism behind the varied binding activities of COXIBs through Molecular Dynamic Simulations, MM-PBSA binding energy calculations and per-residue energy decomposition studies.
Chaudhary N; Aparoy P
J Biomol Struct Dyn; 2017 Mar; 35(4):868-882. PubMed ID: 26982261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
